Thus, approximately 80–85% of invasive breast cancers are classified as HER2-negative (IHC 0, IHC 1 + , and IHC 2 + /ISH-negative) and are not eligible for HER2-targeted therapy. This evidence concerns the gene ERBB2 and invasive breast carcinoma.